Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers.

Lung cancer (Amsterdam, Netherlands) - 1 Nov 2025

Agrawal Prashasti, Rotow Julia, Rocco Gaetano, Travis William, Ortiz Eduardo, Scalabrino Rebecca, LoPiccolo Jaclyn, Facchinetti Francesco, Kris Mark G, Yu Helena A, Jones David, Chaft Jamie E

Abstract excerpt

BACKGROUND: EGFR-inhibitors are currently not approved for neoadjuvant treatment of resectable EGFR-mutant non-small cell lung cancers (NSCLC). We report a real-world multi-institutional analysis of surgical and pathologic outcomes in patients with resectable EGFR-mutant NSCLC treated with neoadjuvant therapies. METHODS: We identified patients with clinical stage II-IIIB NSCLC with sensitizing EGFR mutations who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Indoles

Share to Neoadjuvant Therapy

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 41110381
DOI: 10.1016/j.lungcan.2025.108795
PMCID: PMC12772451

Genes

EGFR
EFS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers.PMID 41110381Read ↗

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.Semantic proximity Read ↗

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.Semantic proximity Read ↗

EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.Semantic proximity Read ↗

Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.Semantic proximity Read ↗

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: a meta-analysisSemantic proximity Read ↗

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.Semantic proximity Read ↗

[Advances in neoadjuvant therapy for EGFR-mutant non-small cell lung cancer].Semantic proximity Read ↗

Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review.Semantic proximity Read ↗

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.Semantic proximity Read ↗

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.Semantic proximity Read ↗

Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.